Launch week offerEnds in00h00m00s
annual Promonthly Pro
Anna Bagnell
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (7)
Year:
2026
Year:
2024
Year:
2024
Transient receptor potential vanilloid 4 (TRPV4), a member of the TRP superfamily, is a broadly expressed, cell surface‐localized cation channel that is activated by a variety of environmental stimuli. Importantly, TRPV4 has been increasingly implicated in the regulation of cellular morphology. Here we propose that TRPV4 and the cytoskeletal remodeling small GTPase RhoA together constitute an environmentally sensitive signaling complex that contributes to pathological cell cytoskeletal alterations during neurological injury and disease. Supporting this hypothesis is our recent work demonstrating direct physical and bidirectional functional interactions of TRPV4 with RhoA, which can lead to activation of RhoA and reorganization of the actin cytoskeleton. Furthermore, a confluence of evidence implicates TRPV4 and/or RhoA in pathological responses triggered by a range of acute neurological insults ranging from stroke to traumatic injury. While initiated by a variety of insults, TRPV4–RhoA signaling may represent a common pathway that disrupts axonal regeneration and blood–brain barrier integrity. These insights also suggest that TRPV4 inhibition may represent a safe, feasible, and precise therapeutic strategy for limiting pathological TRPV4–RhoA activation in a range of neurological diseases.
Year:
2022
Year:
2022
Year:
2022
Year:
2020
Collaborators (3)
Benjamin Gastfriend
University of California, San Diego
Avindra Nath
Clinical Director
National Institutes of Health
Brett A. McCray
-
Make your next move.
Prepare your application
Review drafts before you send them.